

EXHIBIT C

1 o0o

2 A P P E A R A N C E S :

3

4

JOSEPH, HERZFELD, HESTER & KIRSCHENBAUM, LLP
Attorneys for Plaintiffs

757 Third Avenue
25th Floor
New York, New York 10017
BY: MICHAEL DiCHIARA, ESQ.

8

9 JONES DAY

For the Defendant

222 East 41st Street
New York, New York 10017-6702
BY: MICHAEL GRAY, ESQ.

12

13

14 A L S O P R E S E N T :

15

CHAD ACKERMAN, Videographer

16

17

18

19

20

21

22

23

24

25

1 Nicole Mene Guerrera

2 antidepressant differ when you would sell it to
3 hospitals as compared to selling it to private
4 offices?

5 A Yes.

6 Q Can you explain to me how?

7 A Well, hospital sales versus private
8 office sales are very different because when you're
9 in a hospital, you're speaking to pharmacy, you can
10 potentially be speaking to buyers in purchasing,
11 because the hospital needs to purchase the
12 medication to prescribe it to their patients. In
13 this particular situation the inpatient ward,
14 because it was a very potent antidepressant for very
15 severely depressed people.

16 In the private office setting, you
17 don't really have that sort of control, you're not
18 really discussing price point, no one's really
19 buying anything from you, it's different. You're
20 just discussing formulary status, clinical
21 advantages, it's more marketing, it's more
22 promotion.

23 Q When you say formulary status, what
24 does that mean?

25 A It means a doctor is probably not

1 Nicole Mene Guerrera

2 going to write the medication if it's not on a
3 preferred formulary. If it's off formulary, the
4 patient's not going to fill because they're not
5 going to be able to afford it, so it's just not
6 realistic. So it's very important that the
7 medications that you're trying to promote are
8 formulary status, they're on managed care, they're
9 on, you know, Blue Cross-Blue Shield, Oxford,
10 they're on, they're accepted on formularies.
11 Because if they're not, no one's going to be able to
12 go to a drug store and purchase it.

13 Q And when you say it's more marketing
14 and promotion what do you mean by that?

15 A Because when you walk into a private
16 office and you're speaking to physicians, you know,
17 you have a few minutes in between seeing patients
18 and you're really discussing the package insert.
19 You're discussing, you know, the absolute, you know,
20 legal, if you will, sort of speak, that the package
21 insert describes the medication, the
22 pharmacokinetics, the pharmacodynamics, what it does
23 for the body, what it does on the body, side
24 effects, dosing, et cetera. That is really what you
25 do versus talking about what it costs. So it's

1 Nicole Mene Guerrera

2 Q Yeah, in terms of how many visits?

3 A No.

4 Q Still tried to see 10?

5 A Correct.

6 Q How did you decide which doctors to
7 see?

8 A Well, Abbott Laboratories gave us a
9 computer and a call plan of all the doctors we were
10 supposed to see, it wasn't up to me who I saw, it
11 was up to them who I saw.

12 Q In a given day or over a given week?

13 A In a given month. I mean, you got a
14 call plan of doctors period. And we had a routing
15 system that we would take the doctors, divide them
16 up to four and do a four-week call cycle. I also
17 had two other partners I worked with. I called from
18 Jupiter -- I covered from Jupiter to Kendall. One
19 gentleman did Fort Lauderdale to Kendall and one
20 lady did Jupiter to Fort Lauderdale. So I did
21 everyone's geography. I was that third person.
22 Because the whole premise was repeating visiting
23 these doctors over and over and over again, so we
24 had to, the three of us had to sit down and work
25 accordingly on our routing schedules so we wouldn't

1 Nicole Mene Guerrera

2 A Anesthesia.

3 Q Why?

4 A I like selling in the hospital setting
5 much better than the private office setting. That's
6 what I'm doing now actually for Baxter, selling
7 anesthesia. I like reviewing cases. I like
8 learning about the surgeries. It's just more suited
9 for my personality. I felt like in the
10 pharmaceutical setting, the renal care setting, and
11 also what I did with the antibiotics, it was a very
12 canned selling setting. They told us what to say,
13 they told us how to say it, you know, these
14 marketing pieces you couldn't, you couldn't stray
15 from it, you couldn't use your own personality. You
16 know, I felt very, like I was in a box. Whereas
17 when I sell anesthesia -- now granted I sell several
18 different types of anesthesia, remember, for renal
19 care I sold one product, I can have a conversation
20 with the physician, I can learn from him about
21 different cases and different styles of prescribing
22 habits, it's just more interesting to me, I just
23 enjoy it better.

24 Q Was there a type of representative in
25 Mr. DeMascoli's area that was a mirror

1 Nicole Mene Guerrera

2 develop current and future business potential, is
3 that correct, was that one of the expectations?

4 MR. DiCHIARA: Objection. The
5 document speaks for itself, but go ahead, you
6 can answer.

7 A What do you mean future business
8 potential? Well, as far as, we were not able to
9 find doctors, the doctors were given to us, that's
10 the only conflict I have with future business
11 potential. We were to take the doctors in our call
12 plan and hopefully, you know, get them to write a
13 script for Zemplar. We couldn't meet a nephrologist
14 at, you know, at the mall and add them to our call
15 plan. This is very outlined and detailed and
16 specific, we would only call on the doctors that
17 were given to us in our computer and our PDA.

18 Q And the goal once you're assigned a
19 nephrologist is to develop some type of strategy to
20 get that nephrologist to prescribe Zemplar tablets?

21 MR. DiCHIARA: Objection to the form.
22 Go ahead.

23 A I wouldn't say strategy but -- I
24 wouldn't use the word strategy, it was calling on
25 endocrinologists as well as nephrologists, building

1 Nicole Mene Guerrero

2 a relationship, learning their prescribing habits,
3 learning their, their patient population and
4 promoting and marketing Zemplar tablets to them,
5 which was an active form of vitamin D, and, you
6 know, giving them package inserts, some marketing
7 materials, clinical reprints and/or samples if so
8 they would like that.

9 Q How would you learn their prescribing
10 habits?

11 A We had printout data, data from some
12 pharmacies, but for the most part they would tell
13 us. They would just really be very honest and tell
14 us: I write that drug, I don't write that drug. We
15 had some documentation that was given to us from for
16 Abbott Labs. Abbott would retain this information
17 from, from pharmacies that would share that
18 information, because pharmacies don't have to. So
19 we had a little bit of an outline kind of thing, but
20 it was never exact, it was never definite, and a lot
21 of it really came from which, which formulary
22 accepted our products. Formulary status had, I'd
23 say, 98 percent to do with it. Most patients who
24 have renal failure or kidney failure are elderly, a
25 lot of them are on Medicaid/Medicare. I don't

1 Nicole Mene Guerrera

2 messages for your meetings with the doctors?

3 A Core messages.

4 Q Core messages?

5 A Uh-hum.

6 Q And what was a core message?

7 A A core message was what our drug did
8 and how it could, you know, help the patients
9 suffering from this disease.

10 Q And how would you utilize that core
11 message in your sales or promotion of the drugs?

12 A We had marketing pieces with our core
13 message on it, little dosing cards and some clinical
14 reprints, and depending on how the conversation went
15 and what kind of time you got with the doctor,
16 sometimes you get 30 seconds, sometimes you get 10
17 minutes. You never really knew what kind of time,
18 if any, you would get with the physician, so you
19 kind of had it all prepared. Am I going to see him
20 for 30 seconds in the hallway as he's running from
21 room to room? Do I have my samples ready? You're
22 prepared for all the different, you know, canned
23 scripts that Abbott provided us for whatever time,
24 sort of timeline we would receive with the
25 physician, if any.

1 Nicole Mene Guerrera

2 to high prescribing physicians to maximize volume
3 and market share, do you agree that you did that?

4 A Yes. I only called on high
5 prescribing physicians versus Terry and Gabriel.

6 Q Did you help to decide which those --
7 which were the high prescribing physicians or those
8 that would produce greater market share for Abbott
9 Laboratories?

10 A No. That information was given to us.

11 Q In the next operational expectations
12 regarding business processes it talked about how you
13 assessed targets, developed strategic and tactical
14 plans, and updated each trimester, did you do that?

15 A I don't really understand what it
16 means when it say updated each trimester, but.

17 Q Well, let's go to the first part of
18 it.

19 A Okay.

20 Q Did you assess targets and develop
21 strategic and tactical plans?

22 A Yes.

23 Q Did you develop routing schedules?

24 A Yes.

25 Q Did you develop medical education

1 Nicole Mene Guerrera

2 A Yes, I see that, okay, yes.

3 Q Do you know what that means?

4 A I didn't implement strategies.

5 Q Okay.

6 A I went to my key accounts but I didn't
7 decide what I was going to say, I was, I was told
8 what to say based on our medication that we sold to
9 the physician in the disease state but I didn't
10 implement the strategies.

11 Q Okay. And during your career as a
12 renal sales specialist during that year, did you
13 supervise anyone?

14 A No.

15 Q Did you develop any policies,
16 company-wide policies for Abbott during that year?

17 A No.

18 Q Did you develop any company-wide sales
19 strategies for Abbott during that year?

20 A No.

21 Q Did you develop any company-wide
22 marketing strategies for Abbott during that year?

23 A No.

24 Q Okay.

25 MR. DiCHIARA: That's all I have.